저자의 연구 키워드

저자의 연구 키워드

#5-HT3 receptor antagonist

#보조항암화학요법

#비소세포폐암

#시스플라틴

#Acquired resistance

#Actionable mutations

#Adenoid cystic carcinoma

#Adjuvant chemotherapy

#Age groups

#ALK-activated

#ALK-inhibitors

#Analytical validity

#Anaplastic lymphoma kinase

#Angiosarcoma

#Anthracycline

#Anti?PD-1

#Antiemetics

#Antineoplastic agents

#Apoptosis inhibitor 5

#Aromatase inhibitors

#Awareness

#Azasetron

#Bevacizumab

#Blood platelets

#Breast neoplasms

#Carcinoma

#CD56

#CD73

#Ceritinib

#Cervical cancer

#Characteristics

#Chemoradiotherapy

#Chemotherapy

#Circulating tumor DNA

#Cisplatin

#Clinical trial

#Comorbidity

#Crizotinib

#De-escalation

#diffuse

#Diffuse large B-cell lymphoma

#Disease-free survival

#Dolasetron mesylate

#Doxorubicin

#Drug therapy

#Drug-related side effects and adverse reactions

#EGFR C797S mutation

#EGFR kinase domain duplication

#EGFR mutation

#EGFR T790M mutation

#Elderly

#Epidermal growth factor

#Epidermal growth factor receptor

#Epidermal growth factor receptor tyrosine kinase inhibitor

#ErbB receptors

#Erlotinib

#Esophageal neoplasms

#Exemestane

#Gastric Cancer

#Gefitinib

#Gemcitabine

#Glioblastoma

#Glioma

#graves disease

#Head and neck neoplasms

#Health care costs

#High-grade glioma

#Hospices

#Human papillomavirus

#immunoglobulins

#Immunohistochemistry

#Induction chemotherapy

#Infusion-related reaction

#Intensity-modulated radiotherapy

#Interleukin-1beta

#Interstitial lung diseases

#Irinotecan

#Ki-67

#Korea

#KRAS

#large B-cell

#Lazertinib

#Leptomeningeal Metastases

#Leukocytes

#Liquid biopsy

#Lung injury

#Lung neoplasms

#Lymphoma

#Matrix metaloproteinase

#Meta-analysis

#Metastasis

#Myocardial infarction

#Nasal cavity

#Natural killer cells

#Nausea

#Neoadjuvant therapy

#Neoplasm metastasis

#Neoplasms

#Nomograms

#Non?small cell lung carcinoma

#Non-small cell lung cancer

#Non-small cell lung carcinoma

#Non–small cell lung carcinoma

#non-small-cell lung

#Non-small-cell lung carcinoma

#Nutrition status

#Obesity

#Ondansetron

#Orbit evisceration

#Overall survival

#Paclitaxel

#Paranasal sinuses

#Patients

#Pazopanib

#Pemetrexed

#Perception

#Phase II clinical trial

#Platinum

#Poly(ADP-ribose) polymerase inhibitors

#Prognosis

#Prognostic Factor

#Proportional hazards models

#Protein kinase inhibitors

#Radical radiotherapy

#Radiotherapy

#Real-world data

#Receptor

#receptors thyrotropin

#Resistance

#Review

#Rituximab

#Serotonin antagonists

#Skin

#Small cell lung carcinoma

#SMARCA4

#SMARCB1

#Solid Tumor

#Targeted molecular therapy

#Taxane

#Terminal care

#Thromboembolism

#Thymus hyperplasia

#thyroid-stimulating

#Tonsil neoplasms

#Transforming growth factor beta1

#Trend

#Tyrosine kinase inhibitor

#Undifferentiated tumor

#Vascular endothelial growth factor

#Vinorelbine

#Volition

#Vomiting

#Vomiting/chemically induced

#Vomiting/prevention and control